blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2091910

EP2091910 - CRYSTALLINE FORMS OF (3 S) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-OXOPENTA NOIC ACID [Right-click to bookmark this link]
Former [2009/35]CRYSTALLINE FORMS OF ( 3 S ) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-0X0PENTA NOIC ACID
[2014/18]
StatusNo opposition filed within time limit
Status updated on  26.06.2015
Database last updated on 01.10.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): MT		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Conatus Pharmaceuticals, Inc.
16745 W. Bernardo Drive, Suite 200
San Diego, CA 92127 / US
[2014/51]
Former [2013/27]For all designated states
Conatus Pharmaceuticals, Inc.
4365 Executive Drive Suite 200
San Diego, CA 92121 / US
Former [2010/43]For all designated states
Idun Pharmaceuticals, Inc.
9380 Judicial Drive
San Diego, CA 92121 / US
Former [2009/35]For all designated states
PFIZER INC.
235 East 42nd Street
New York, New York 10017 / US
Inventor(s)01 / DIMOCK, Stuart
24144 Grayston Drive
Lake Forest, CA 92630 / US
02 / HAGEN, Eric
1123 Trillium Lane
Lafayette, Indiana 47905 / US
03 / HANKO, Jason
4301 Antiquity Court
West Lafayette, Indiana 47906 / US
 [2009/35]
Representative(s)Savic, Bojan, et al
Jones Day
Rechtsanwälte Attorneys-at-Law Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2013/52]
Former [2010/43]Ritter, Thomas Kurt, et al
Jones Day Prinzregentenstrasse 11
80538 München / DE
Former [2009/35]Motion, Keith Robert
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date07859033.803.12.2007
[2009/35]
WO2007IB03900
Priority number, dateUS20060868748P06.12.2006         Original published format: US 868748 P
[2009/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008068615
Date:12.06.2008
Language:EN
[2008/24]
Type: A1 Application with search report 
No.:EP2091910
Date:26.08.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 12.06.2008 takes the place of the publication of the European patent application.
[2009/35]
Type: B1 Patent specification 
No.:EP2091910
Date:20.08.2014
Language:EN
[2014/34]
Search report(s)International search report - published on:EP12.06.2008
ClassificationIPC:C07C237/22, A61K31/197, A61P1/16
[2009/35]
CPC:
C07C237/22 (EP,NO,US); C07C235/74 (KR); A61K31/167 (KR);
A61K31/197 (NO); A61P1/16 (EP); C07C235/52 (KR);
C07B2200/13 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/35]
TitleGerman:KRISTALLINE FORMEN VON (3 S) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-OXO-PENTANSÄURE[2014/18]
English:CRYSTALLINE FORMS OF (3 S) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-OXOPENTA NOIC ACID[2014/18]
French:FORMES CRISTALLINES DE L'ACIDE (3 S) -3- [N- (N' - (2-TERT-BUTYPHENYL) OXAMYL) ALANINYL] AMINO-5-(2 ',3 ',5 ',6 ' -TETRAFLUOROPHENOXY) -4-OXOPENTANOIQUE[2014/18]
Former [2009/35]KRISTALLINE FORMEN VON ( 3 S ) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-0X0-PENTANSÄURE
Former [2009/35]CRYSTALLINE FORMS OF ( 3 S ) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-0X0PENTA NOIC ACID
Former [2009/35]FORMES CRISTALLINES DE L'ACIDE ( 3 S ) -3- [N- (N' - (2-TERT-BUTYPHENYL) OXAMYL) ALANINYL] AMINO-5-(2 ',3 ',5 ',6 ' -TETRAFLUOROPHENOXY) -4-OXOPENTANOIQUE
Entry into regional phase06.07.2009National basic fee paid 
06.07.2009Designation fee(s) paid 
06.07.2009Examination fee paid 
Examination procedure06.07.2009Examination requested  [2009/35]
01.04.2010Despatch of a communication from the examining division (Time limit: M04)
07.07.2010Reply to a communication from the examining division
18.04.2013Despatch of a communication from the examining division (Time limit: M04)
18.07.2013Reply to a communication from the examining division
11.04.2014Communication of intention to grant the patent
08.07.2014Fee for grant paid
08.07.2014Fee for publishing/printing paid
08.07.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.04.2010
Opposition(s)21.05.2015No opposition filed within time limit [2015/31]
Fees paidRenewal fee
04.01.2010Renewal fee patent year 03
15.12.2010Renewal fee patent year 04
12.12.2011Renewal fee patent year 05
11.12.2012Renewal fee patent year 06
12.12.2013Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY20.08.2014
EE20.08.2014
LT20.08.2014
LV20.08.2014
MC20.08.2014
MT20.08.2014
SI20.08.2014
SK20.08.2014
BG20.11.2014
IS20.12.2014
[2016/33]
Former [2016/31]CY20.08.2014
EE20.08.2014
LT20.08.2014
LV20.08.2014
MC20.08.2014
SI20.08.2014
SK20.08.2014
BG20.11.2014
IS20.12.2014
Former [2016/27]EE20.08.2014
LT20.08.2014
LV20.08.2014
MC20.08.2014
SI20.08.2014
SK20.08.2014
BG20.11.2014
IS20.12.2014
Former [2015/50]EE20.08.2014
LT20.08.2014
LV20.08.2014
SI20.08.2014
SK20.08.2014
BG20.11.2014
IS20.12.2014
Former [2015/23]EE20.08.2014
LT20.08.2014
LV20.08.2014
SK20.08.2014
BG20.11.2014
IS20.12.2014
Former [2015/12]LT20.08.2014
LV20.08.2014
BG20.11.2014
IS20.12.2014
Former [2015/10]LT20.08.2014
BG20.11.2014
Former [2015/08]LT20.08.2014
Cited inInternational search[A]US2002042376  (KARANEWSKY DONALD S [US], et al) [A] 1-15 * example 126 *;
 [A]  - STEVEN D. LINTON ET AL, "First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease", J. MED. CHEM., (20050610), vol. 48, no. 22, pages 6779 - 6782, XP002474577 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm050307e
 [A]  - STEVEN D. LINTON ET AL, "First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease", J. MED. CHEM., (20050610), vol. 48, no. 22, pages 1 - 23, XP002474578 [A] 1-15 * Supporting information pages 22 and 23. *

DOI:   http://dx.doi.org/10.1021/jm0400101
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.